Pharma Industry News
Printable Version   Email to a friend

Statins Found to Have Wider Benefit

October 1, 2005

Two groups of researchers have found that statin drugs, used to lower cholesterol, may offer additional, unexpected health benefits.

Statins may offer protection against heart attack and stroke in diabetic and high-risk patients, and against bone-fracture risk in elderly men, according to two reports by Reuters, published 26 September 2005.

Statin Stats

Statins are used by millions of people worldwide to reduce high cholesterol levels. Low-density lipoproteins-" LDL"- is known as "bad cholesterol" because it deposits fat inside the arteries, while high-density lipoproteins - "HDL"-is "good cholesterol" because it carries the fat away.

Statins lower cholesterol by inhibiting an enzyme necessary in producing cholesterol in the body. The most popular statins include Pfizer's Lipitor, Merck's Zocor and AstraZeneca's Crestor. High cholesterol, diabetes, smoking, obesity and high blood pressure are all risk factors for heart disease.

Cardiovascular Benefit

A team of British researchers has shown the benefits of statins may extend to protection against cardiovascular events.

Lowering cholesterol using a statin may reduce risk of stroke or heart attack by up to one-third, according to study co-ordinator Dr Colin Baigent, an epidemiologist at Britain's Medical Research Council (MRC).

"What we have shown is that the key thing is to find people who are at risk of coronary heart disease or stroke and treat them with a regimen that reduces LDL cholesterol substantially," Baigent said, according to Reuters.

"The size of the reduction in the risk of major vascular events-coronary heart disease or stroke-- is proportional to the size of the absolute reduction in LDL cholesterol."

Baigent and colleagues reviewed results of 14 previous trials that involved treating about 90,000 people with statins. Results showed that high-risk patients with low cholesterol showing a high level of benefit, and people with the largest cholesterol reduction showed the most significant benefit.

The amount of cholesterol reduction is also important, according to Professor Anthony Keech, of the National Health Medical Research Council at the University of Sydney, co-ordinator of the study team in Australia.

"So, bigger cholesterol reductions with more intensive treatment regimens should lead to great benefits," said Keech, according to Reuters.

Statins Reduce Fracture Risk

A study of mostly elderly men has shown that statins may reduce the risk of bone fracture, according to a report by Reuters. In contrast, previous research conducted primarily with women showed mixed results concerning the link between statins and fracture risk.

The new study represents one of the largest studies to date and is reported in the Archives of Internal Medicine by Dr. Richard E. Scranton, of Harvard Medical School in Boston, and colleagues. Of a total 91,052 patients (approximately 95% male) studied, 28,063 were prescribed statins, 2,195 were prescribed non-statin lipid-lowering medications and 60,794 received no lipid-lowering medications.

In an analysis of data adjusted for a variety of individual factors, such as age, weight, presence of osteoporosis and other disorders and other medications, investigators found statin use was associated with a 36% reduction in fracture risk compared with no lipid-lowering therapy and a 32% reduction compared with non-statin lipid-lowering therapy.

When data were examined by dose, patients taking the highest statin doses were 50% less likely to suffer a fracture, compared with patients taking the lowest doses.

According to investigators, further studies are needed that examine the connection between statin use and protection against fractures.

Sources:
Scientists find wider uses for cholesterol drugs, Reuters, 26 September 2005.
'Statin' drugs reduce fracture risk in men, Reuters, 26 September 2005.
Statin Use and Fracture Risk: Study of a US Veterans Population, Richard E. Scranton et al., Archives of Internal Medicine, volume 165, pages 2007-2012, 26 September 2005.

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


MedNotes
Latest FDA Drug Alerts
November 17, 2008
Audience: Consumers, dermatologists, pharmacists, other healthcare professionals[Posted 11/17/2008] CSI USA Inc. and FDA informed...
November 12, 2008
Audience: Consumers, pediatricians, other healthcare professionals[Posted 11/12/2008] Johnson & Johnson, Merck Consumer...
November 12, 2008
Audience: Geriatricians, gynecologists, orthopedic surgeons, other healthcare professionals[Posted 11/12/2008] FDA issued an...
November 10, 2008
Audience: Pharmacists, other healthcare professionals, patients [Posted 11/10/2008] Ethex Corp and FDA notified healthcare...
More...
Latest Drug Information Updates

Apriso
Apriso (mesalamine) is a once-daily, locally-acting aminosalicylate indicated for the maintenance of remission of ulcerative colitis (UC) in adults.

LoSeasonique
LoSeasonique is a lower-dose, extended-cycle oral contraceptive indicated for the prevention of pregnancy.

Acanya
Acanya (benzoyl peroxide and clindamycin phosphate) is a topical antibacterial and antibiotic combination for the treatment of acne.

Toviaz
Toviaz (fesoterodine fumarate) is a competitive muscarinic receptor antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.

Vimpat
Vimpat (lacosamide) is an anti-convulsant drug for the treatment of partial onset seizures in adults with epilepsy.

Astepro
Astepro (azelastine) is a nasal antihistamine for the treatment of seasonal allergic rhinitis.

Rapaflo
Rapaflo (silodosin) is an alpha(1)- adrenoreceptor antagonist for the treatment of the signs and symptoms associated with benign prostatic hyperplasia (BPH), or enlarged prostate.

Cinryze
Cinryze is a C1-esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE).

Akten
Akten (lidocaine hydrochloride) Ophthalmic Gel is a topical, ocular anesthetic formulation for use in ocular procedures that require a topical anesthetic agent.

AdreView
AdreView is a diagnostic radiopharmaceutical agent indicated for use in the detection of rare neuroendocrine tumors in children and adults.

Sancuso
Sancuso (granisetron transdermal system) is an anti-emetic transdermal delivery system indicated for the control of nausea and vomiting in patients receiving moderately and/or highly nausea-inducing chemotherapy.

Nplate
Nplate (romiplostim) is a thrombopoietin mimetic peptibody for the treatment of thrombocytopenia in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP).

Xenazine
Xenazine (tetrabenazine) is a selective and reversible centrally-acting dopamine depleting drug indicated for the treatment of chorea associated with Huntington's disease.

Cleviprex
Cleviprex is an intravenous, ultrashort-acting calcium channel blocker under development for the treatment of severely elevated blood pressure in the hospital setting when oral therapy is not feasible or desirable.

Stavzor
Stavzor is delayed-release valproic acid formulated in the EnteriCare enteric soft gelatin capsule delivery system designed to minimize GI adverse events. Stavzor is indicated for the treatment of manic episodes associated with bipolar disorder, adjunctive therapy in multiple seizure types (including epilepsy), and prophylaxis of migraine headaches.

More...